Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 8, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease.

A E Warrington1, M Rodriguez

  • 1Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Warrington.arthur@mayo.edu

Current Topics in Microbiology and Immunology
|January 29, 2008
PubMed
Summary

Antibodies targeting central nervous system (CNS) antigens can promote remyelination after injury. A specific human IgM antibody (rHIgM22) effectively induces repair in CNS injury models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes.

Glia·2010
Same author

Immunoglobulin-mediated CNS repair.

The Journal of allergy and clinical immunology·2001
Same author

Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

Proceedings of the National Academy of Sciences of the United States of America·2000
Same author

Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Journal of virology·1995
Same author

Epidemiology of hepatitis D virus infection: changes in the last 14 years.

The American journal of gastroenterology·1995
Same author

Comparison of Z and multivariate statistical brain electromagnetic maps for the localization of brain lesions.

Electroencephalography and clinical neurophysiology·1995

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Central nervous system (CNS) injuries, like spinal cord injury and multiple sclerosis (MS), lead to axonal damage and disability.
  • Remyelination, the process of restoring myelin sheaths, is a key neuroprotective strategy.
  • Endogenous myelinating cells and progenitors are present in CNS lesions, suggesting therapeutic potential.

Purpose of the Study:

  • To review the use of antibodies reactive to CNS antigens for promoting remyelination.
  • To explore the therapeutic potential of antibody-induced remyelination in CNS disorders.
  • To highlight novel remyelination-promoting antibodies as a distinct therapeutic approach.

Main Methods:

  • Review of studies investigating antibody-induced remyelination in CNS injury models.

More Related Videos

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
06:07

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System

Published on: December 17, 2021

Related Experiment Videos

Last Updated: Jul 8, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
06:07

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System

Published on: December 17, 2021

  • Identification and characterization of CNS-reactive antibodies, including monoclonal IgMs.
  • Evaluation of a recombinant human IgM (rHIgM22) for its remyelination efficacy and mechanism.

    • Main Results:

    • Antibodies reactive to CNS antigens can induce remyelination in models of chronic spinal cord injury.
    • Monoclonal IgMs binding to oligodendrocytes and myelin were identified as functionally equivalent to antisera.
    • A single low dose of rHIgM22 promoted maximal remyelination within 5 weeks in CNS injury models.

    Conclusions:

    • Antibodies, particularly the IgM isoform, show significant potential for promoting remyelination in the CNS.
    • rHIgM22 is a promising therapeutic candidate for inducing tissue repair in CNS injuries.
    • Remyelination-promoting IgMs represent a novel therapeutic strategy focused on tissue repair, distinct from current anti-inflammatory MS treatments.